Cerebral Cavernous Malformation

About this condition

Cerebral Cavernous Malformation

A vascular malformation in the brain characterized by clusters of abnormally enlarged, thin-walled capillaries.

Cerebral cavernous malformations (CCM) are abnormal clusters of dilated blood vessels in the brain predisposed to hemorrhage. Familial CCM (approximately 50% of cases) follows autosomal dominant inheritance; the remaining cases involve single sporadic lesions. CCM manifests with hemorrhagic stroke, seizures, and progressive neurological deficits ranging from mild cognitive changes to severe disability. Hemorrhage rate for familial forms is approximately 0.7 to 1.1% per lesion per year. Three genes cause familial CCM: KRIT1 (encoding a scaffolding protein), CCM2, and PDCD10 (programmed cell death 10, an apoptosis-related protein). These proteins form the CCM complex regulating endothelial cell-cell adhesion and barrier function.

Familial CCM prevalence is estimated at 1 in 5,000 to 1 in 10,000 in Hispanic Americans due to founder mutation effects. KRIT1 mutations account for approximately 50% of familial CCM; CCM2 accounts for a minority; PDCD10 accounts for approximately 20% but is associated with a markedly more severe phenotype. Critically, PDCD10 mutations are associated with significantly more aggressive disease: earlier age of onset, greater number of lesions, higher hemorrhage rate, and additional manifestations including scoliosis and perioral skin lesions. Approximately 80% of carriers of a familial CCM variant develop detectable lesions by adulthood. Approximately 10 to 20% of familial CCM cases remain genetically unresolved, suggesting additional undiscovered genes.

A pathogenic variant in KRIT1, CCM2, or PDCD10 confirms familial CCM and mandates surveillance of all first-degree relatives with brain MRI; approximately 80% of carriers develop detectable lesions by adulthood. Genotype-phenotype correlation is critical: PDCD10-positive families should expect more aggressive disease with earlier onset, more lesions, higher hemorrhage risk, and additional systemic manifestations. These patients require closer neuroradiologic surveillance and lower thresholds for surgical intervention. Symptomatic CCM lesions (those causing seizures or hemorrhage) warrant neurosurgical evaluation; asymptomatic superficial lesions may be monitored conservatively. Genetic diagnosis enables genetic counseling and cascade family screening, identifying at-risk presymptomatic carriers who benefit from surveillance protocols.

PDCD10 mutations cause significantly more aggressive disease with earlier onset, greater lesion burden, higher hemorrhage rates, and additional systemic manifestations like scoliosis and perioral skin changes.

Why whole genome sequencing

CCM genetic testing is underutilized despite high value for family surveillance. 10 to 20% of familial cases remain genetically unresolved, suggesting additional genes.